Innovative first-in-class products comprise 30% of diabetes complications pipeline
New targets need to be identified and converted into improved therapeutic options, particularly in order to develop therapies more aligned with the underlying disease pathophysiology, says GBI Research.
The diabetes complications space has high potential for changes and improvements as it becomes more diverse, with 30% of diabetic complication products in active development considered to be first-in-class, according to business intelligence provider GBI Research.
According to the company’s latest report — Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies — the market for diabetic complications is predominantly composed of therapies that symptomatically treat the condition and, at best, slow disease progression. However, as the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options, particularly in order to develop therapies that are more aligned with the underlying disease pathophysiology.
Firas Nour, Associate Analyst for GBI Research, states that: “Although many first-in-class products fail to make an impact on the market even upon successful regulatory approval, higher-risk programs for innovative first-in-class products remain attractive and have led to some of the most clinically and commercially successful products of the past decade, including Avastin (bevacizumab) for diabetic macular edema and Rituxan (rituximab) for diabetic neuropathy.”
GBI Research has found that 31.7% of products in the entire metabolic pipeline are first-in-class, which means that diabetic neuropathies have a below-average proportion of first-in-class pipeline products. In the diabetic retinopathies segment, however, there is substantial innovation in the early pipeline, which offers signs that a greater proportion of first-in-class products will filter through to Phase III in the future.
Deal activity within the diabetic complications market varies with first-in-class status. Strategic consolidations have played an important role in developing therapeutics for diabetic complications in the past decade, with 81 licensing deals and 36 co-development deals having taken place since 2006.
Nour continues: “The deals in diabetic complications revealed that licensing deals did not reflect the industry-wide trend of first-in-class deals being more valuable. Co-development deals, meanwhile, were representative of the overall picture of the complications pipeline, reflecting the shift towards therapies that are more aligned with the underlying disease pathophysiology.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance